首页> Seminars in arthritis and rheumatism> Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort.

Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort.

导出 LinkOut

翻译打印收藏纠错

第一作者： Koji,Suzuki

第一单位： Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: ksuzuki0418@keio.jp.

作者： Koji,Suzuki ^[1] ; Mitsuhiro,Akiyama ^[2] ; Kanako,Shimanuki ^[3] ; Hiroyuki,Fukui ^[4] ; Yuko,Kaneko ^[5]

作者单位： Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: ksuzuki0418@keio.jp. ^[1] Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: mitsuaki@keio.jp. ^[2] Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: k.shimanuki@keio.jp. ^[3] Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: hiroyukifukui@keio.jp. ^[4] Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: ykaneko.z6@keio.jp. ^[5]

关键词 Antifibrotic agents Interstitial lung disease Nintedanib Progressive pulmonary fibrosis Systemic autoimmune rheumatic disease